Revised SPC: Bydureon (exenatide) 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen

New dosing information added to SPC states that no dose adjustment is necessary for patients with mild or moderate renal impairment.

Source:

electronic Medicines compendium